L10 Tumor Lysis Syndrome (Dixit and Santhosh)

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/68

encourage image

There's no tags or description

Looks like no tags are added yet.

69 Terms

1
New cards

pt is at low risk for TLS. What should you treat them with?

  1. hydration

  2. uric acid: consider allopurinol if indicated based on malignancy/treatment risk

  3. risk-based monitoring: baseline and periodic TLS monitoring


2
New cards

pt is at intermediate risk for TLS. What should you treat them with?

  1. IV hyration as tolerated

  2. frequent labs

  3. uric acid: allopurinol or alt XO inhibitor

  4. assess outpatient vs inpatient monitoring


3
New cards

pt is at high risk for TLS. What should you treat them with?

  1. IV hydration as tolerated w fluid balance and urine output assessment

  2. close labs/ consider telemetry

  3. rasburicase if appropriate; assess G6PD status

  4. assess inpatient monitoring


4
New cards

pt has established TLS What should you treat them with?

  1. immediate care: urgent correction of abnormalities

  2. individualized isotonic IV fluids

  3. frequent labs, ECG, and urine output

  4. rasburicase if appropriate, monitor response

  5. escalation: intensive monitoring, nephrology/dialysis if indicated


5
New cards

What should you monitor for patients at risk for TLS before starting therapy?

baseline K, Phos, Ca, uric acid, Cr, LDH and volume status

6
New cards

What should you monitor for patients at risk for TLS during risk period?

  • repeat electrolytes, uric acid, kidney function based on risk, therapy and thrends

  • monitor urine output and fluid balance


7
New cards

When should you escalate monitoring in pts at risk for TLS?

increase freq w laboratory changes, oliguria, arrhythmia risk or established TLS

8
New cards

When should you consider inpatient observation/telemetry for pts at risk for TLS?

pt is high risk or clinically unstable; use therapy-specific monitoring schedules

9
New cards

Describe hydration for TLS management. What is the target urine output?

isotonic IV crystalloids; individualize fluids to volume status, cardiac function and renal function

  • target: 2mL/kg/hr

  • avoid nephrotoxins!!


10
New cards

Loop diuretics are not routinely recommended for TLS prophylaxis and do NOT reaplce adequate hydration. When is it considered?

when pt has fluid overload after assesssing volume status

11
New cards

When should nephrology/renal reaplacement therapy be initiated for TLS therapy?

  1. pt has refractory hyperkalemia, severe or worsening hyperphosphatemia, or symptomatic hypocalcemia with hyperphosphatemia

  2. for fluid overload or severe AKI; dialysis isn’t required for every pt


12
New cards

What is the management strategy for potassium in TLS?

  1. frequent monitoring + ECG monitoring of calcium gluconate

  2. avoid IV and oral K

  3. Sodium polystyrene sulfonate

  4. Sodium zirconium cyclosilicate

  5. Regular IV insulin/D50W

  6. Albuterol

  7. Sodium bicarbonate

  8. Loop diuretics

  9. Dialysis


13
New cards

What is the management strategy for phosphate in TLS?

  • Avoid IV phosphate administration

  • Phosphate binders (Sevelamer)

  • Dialysis


14
New cards

What is the management strategy for calcium in TLS?

If symptomatic, calcium gluconate IV administered slowly with ECG monitoring

15
New cards

What are the manifestations of hyperkalemia?

  1. serum K >5 mEq/L

  2. earliest EKG change: peaked T waves

  3. often asymptomatic; may experience palpitations


16
New cards

What is consider mild, moderate and severe hyperkalemia?

  1. Mild: 5-5.9 mEq/L

  2. Moderate: 6-6.9 mEq/L

  3. Severe hyperkalemia: ≥7 mEq/L


17
New cards

What is the general approach for acute moderate to severe hyperkalemia? (>6 mEq/L)


immediate treatment with an agent that lowers K to <5 mEq/L quickly as EKG changes may start to occur at 5.5-6mEq/L

18
New cards

pt has moderate to severe hyperkalemia (>6 mEq/L), how should you treat them?

  1. obtain EKG: if changes are present, stabilize cardiac membrane with Ca2+, then give agents to lower K quickly. If no changes then proceed with K lowering agents.

  2. admin agents to lower K quickly: IV regular insulin


19
New cards

First line agent to lower K quickly

IV regualr insulin

20
New cards

How can you stabilize the cardiac cell membrane?

  1. calcium gluconate 1-3g IV/IM

  2. OR calcium chloride 1 g IV


21
New cards

What is the MOA of calcium?

raises cardiac membrane potential and stabilize myocardium (onset 1-2min) HAS NO EFFECT ON SERUM K

22
New cards

Which calcium agent is more preferred and why?

calcium gluconate is preferred bc calcium chloride can cause extravasation and tissue necrosis

23
New cards

Potassium shifters shift potassium intracellularly by stimulating the Na/K ATPase pump. What is the first line agent for this?

IV insulin regular (humulin R/Novolin R) ± dextrose

24
New cards

how much IV insulin should you give when pt has renal insufficiency vs they don’t have renal insufficiency?

  1. no renal insuff: 10 units

  2. has renal insuff: 5 units


25
New cards

When administering IV insulin regular ± dextrose, when should you omit the dextrose component?

glucose >250g/dL

26
New cards

What are additional potassium shifter agents that may be considered for hyperkalemia?

  1. nebulized albuterol 10-20mg over 10 min

  2. sodium bicarb 50mEq IV


27
New cards

When should you consider sodium bicarbonate 50mEq IV in TLS hyperkalemia?

in pts with concurrent metabolic acidosis (controversial)

28
New cards

TLS pt has mild hyperkalemia without any symptoms or EKG changes. What can you give them?

  1. SPS(Kayexalate)

  2. SZC (Lokelma)

  3. Furosemide

  4. Dialysis


29
New cards

What are the clinical pearls about SPS (Kayexalate)?

  1. MOA: cation exchange resin that binds K+ in intestines and excreted in the feces

  2. 15-30g PO OR 30-50g rectal enema

  3. hours to days effect

  4. formulated w sorbitol to dec constipation → GI necrosis


30
New cards

What are the clinical pearls of SZC (Lokelma)?

  1. moa: cation exchange resin that binds to K+ in the intesintes and excreted via feces

  2. dose: 10g PO TID for up to 48rs

  3. onset: 1hr

  4. peak fx at 2 hr

  5. lower rate of GI fx compared to SPS


31
New cards

What are the clinical pearls about furosemide (Lasix)?

  1. moa: loop diuretic that inhib reabsorpt of sodium and chloride in ascending loop of henle and prox and distal renal tubules

  2. dose: 40-80mg IV

  3. onset: 5-30min

  4. adjunctive therapy for pts who are fluid overloaded


32
New cards

What are the manifestations of hyperphosphatemia

  1. serum phosphate >4.5 mg/dL

  2. GI upset: N/V/D

  3. Neurologic: altered mental status, lethargy, seizures

  4. Ca-PO4 precipitate can exacerbate renal failure


33
New cards

What is the treatment for hyperphosphatemia? What is the MOA?

  1. phosphate binder

  2. moa: reduces absorption of dietary phosphate in GI tract, by exchanging anion phosphate with an active cation to form a nonabsorbable compound that gets excreted in the feces


34
New cards

What are examples of phosphate binders?

  1. sevelamer carbonate (renvela)

  2. calcium carbonate (tums) or calcium acetate (phoslo)

  3. aluminum hydroxide


35
New cards

What are the clinical pearls of sevelamer carbonate (Renvela)?

  1. Dose by phosphate level:

    1. >5.5 to <7.5 mg/dL: 800 mg TID with meals

    2. 7.5 to <9 mg/dL: 1,200 to 1,600 mg TID with meals

    3. ≥9 mg/dL: 1,600 mg TID with meals

  2. Dosing not studied in TLS -> extrapolated from CKD dosing


36
New cards

What are the clinical pearls of calcium carbonate and calcium acetate?

  1. Dose: 500 - 1000 mg of elemental calcium PO TID with meals

  2. Carbonate = 40% elemental calcium, acetate = 25% calcium

  3. Can bind with phosphate and potentially precipitate renal failure


37
New cards

What are the clinical pearls of aluminum hydroxide?

  1. Dose: 300 - 600 mg PO TID with meals

  2. Limit duration due to risk for aluminum toxicity (encephalopathy, osteomalacia, microcytic anemia)


38
New cards

What should you give to treat hyperuricemia?

  1. allopurinol

  2. rasburicase

  3. sodium bicarbonate


39
New cards

which hyperuricemia agent prevents conversion of xanthine and hypoxanthine to uric acid? (MOA: inhibits xanthine oxidase, preventing conversion of xanthine and hypoxanthine uric acid) and what is the dose?

  1. allopurinol

    1. PO: 300mg/m²/d OR 10mg/kg/d divided every 8 hrs (max 800mg); typical dose 300mg QD or BID

    2. IV: 200-400mg/m²/d in 1-3 divided doses


40
New cards

What are the ADE of allopurinol?

  1. n/d

  2. increased LFTs

  3. hypersensitivity (SJS, toxic epidermal necrolysis)


41
New cards

What are the limitations of allopurinol?

  1. ineffective at reducing levels of uric acid already developed

  2. Leads to buildup of xanthine and hypoxanthine metabolites → Xanthine nephropathy

  3. DDI: Decreases clearance of purine analogs (6- mercaptopurine, azathioprine)


42
New cards

which hyperuricemia agent is a recombinant urate oxidase that converts uric acid to allantoin and decreases serum uric acid levels within 4 hrs?

rasburicase

  • Manufacturer’s labeling: 0.2 mg/kg IV daily for up to 5 days


43
New cards

What is the fixed dosing approach for rasburicase?

3-7.5mg as a single dose based on serum uric acid levels

44
New cards

What are the CI of rasburicase(elitek)

  1. Hypersens

  2. ho hemolytic rxn or methemoglobinemia w rasburicase

  3. Glucose-6-phosphate dehydrogenase (G6PD) def


45
New cards

What are the BBW of rasburicase?

  1. Hypersensitivity reactions

  2. Methemoglobinemia

  3. Hemolysis in G6PD deficiency

  4. Interference with uric acid measurements


46
New cards

What BBW of rasburicase requires screening before initiation?

Hemolysis in G6PD deficiency: Screen patients at high risk (African or Mediterranean ancestry) prior to starting rasburicase


47
New cards

which hyperuricemia agent inc solubility of uric acid, dec solubility of calcium phosphate. It also may lead to metabolic alkalosis and is NOT routinely utilized to manage hyperuricemia

sodium bicarbonate

48
New cards

Febuxostate (Uloric) is a xanthine oxidease inhibitor FDA approved to treat hyperuricemia. What is the florence trial?

mean seruc uric acid was significantly lower in febuxostate group (pts with hematologic malignancies at intermediate to high risk TLS)

49
New cards

What are the ADE of febuxostat? CI?

ADE: LFT abnormal, n, arthralgia, rash, severe skin rxns (SJS, DRESS, TEN)

CI: concurrent use of azathioprine or mercaptopurine

50
New cards

What is the BBW of febuxostat?

Gout patients with established cardiovascular disease treated with febuxostat had a higher rate of CV death compared to those treated with allopurinol in a CV outcomes study

51
New cards

What is TLS?

oncologic emergency: rapid large-scale destruction of malignant cells releases IC contents faster than the body can clear them

  • occurs within days of starting chemo


52
New cards

When is TLS common?

hematologic malignancies (acute leukemias, aggressive lymphomas), but also reported after radiation, intrathecal chemo and in solid tumors

  • venetoclax, CAR T cells, bispecific ABX cause TLS in low risk diseases


53
New cards

T/F early recognition of TLS and prevention of TLS reduces kidney injury and death

true

54
New cards

What are the disease (tumor) factors of TLS?

  1. Histology: Burkitt, lymphoblastic lymphoma, ALL, AML, aggressive (high-grade) lymphoma

  2. High tumor burden: bulky mass >10 cm, WBC ≥100 × 10⁹/L, advanced stage

  3. LDH > upper limit of normal (ULN), especially ≥2× ULN

  4. High proliferation rate (e.g., high Ki-67)

  5. Bone marrow or organ (incl. renal) inflammation


55
New cards

What are the patient risk factors of TLS?

  1. Pre-existing kidney dysfunction or renal involvement

  2. Dehydra, volume deple, HoT

  3. Pre-existing hyperuric, hyperphos or hyperkal

  4. NSAIDs, ACEi/ARB, SGLT2i, metformin, K⁺-sparing diuretics

  5. Frailty; unable to maintain oral fluid intake


56
New cards

Look at this chart (TLS risk by disease)


57
New cards

SEQ pathophysiology of TLS

  1. DNA → purines → hypoxanthina → xanthine → uric acid by XO

  2. malignant cells: 4x phosphate lvls

  3. potassium: released directly into plasma

  4. cytokines: cause HoT and inflamm → kidney injury

AKI AND TLS IS A CYCLE

58
New cards

Why does the kidney fail?

  1. uric acid nephropathy

  2. calcium phosphate deposition

  3. xanthine nephropathy


59
New cards

describe uric acid nephropathy

  1. uric acid pKa = 5.4

  2. crystals obstruct tubules

  3. crystal independent injury: renal vascons, impaired autoreg, oxidative stress, inflamm


60
New cards

describe calcium phosphate deposition

  1. high phosphate binds calcium

  2. precipitates in tubules and tissues (nephrocalcinosis)

  3. risk rises sharlply when Ca x PO4 product >= 60 mg²/dL²

  4. leads to secondary hypocalcemia


61
New cards

describe xanthine nephropathy

  1. xanthine is less soluble than uric acid

  2. accum when XO is blocked (allopurinol, febuxostat)

  3. not measure routinely, suspect if kidney function worsens on therapy


62
New cards

which clinical manifestation is this: Cardiac arrhythmias (peaked T waves, widened QRS, VT/VF, cardiac arrest); muscle weakness, cramps, paresthesias

hyperkalemia

63
New cards

which clinical manifestation is this: Nausea, vomiting, diarrhea, lethargy, seizures; Ca- PO₄ precipitation worsens AKI

hyperphosphatemia

64
New cards

which clinical manifestation is this: Tetany, cramps, paresthesias, Chvostek/Trousseau signs, prolonged QT, arrhythmias, hypotension, seizures

hypocalcemia (secondary)

65
New cards

which clinical manifestation is this:Usually silent until AKI: oliguria/anuria, flank pain, hematuria; fluid overload, edema

hyperuricemia

66
New cards

which clinical manifestation is this: Worsens every abnormality above by reducing clearance (vicious cycle

acute kidney injury

67
New cards

What is considered laboratory TLS? (Cairo bishop criteria)

  1. uric acid: >= 8mg/dL

  2. potassium: >=6 mEq/L

  3. phosphate: >= 4.5 mg/dL adults

  4. calcium: =<7 mg/dL

>=2 of these within the same 24 hrs


68
New cards

What is considered clinical TLS? (cairo bishop criteria)

  1. laboratory TLS PLUS

  2. one or more of the following:

    1. creatinine: >=1.5 x ULN

    2. cardiac arrhythmia

    3. seizure

    4. sudden death


69
New cards

what are the refinements of clinical TLS

  1. any symptomatic hypocalcemia counts as clinical TLS

  2. kidney criterion as AKI: Cr rise >0.3mg/dL, single value >1.5 ULN or urine output <0.5ml/kg/h for 6h